STOCK TITAN

Royalty Pharma plc (RPRX) Stock News, Jun 18, 2020

RPRX NASDAQ

Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.

Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.

Rhea-AI Summary

Royalty Pharma plc (NASDAQ: RPRX) has successfully completed its initial public offering (IPO) of 89,333,920 Class A ordinary shares, priced at $28.00 each. The IPO size increased from an initial 70 million shares, reflecting strong demand. The company issued 71,652,250 shares, while selling shareholders contributed 17,681,670 shares. The offering included the full exercise of underwriters' options for an additional 11,652,250 shares. Trading began on June 16, 2020, on the Nasdaq Global Select Market under the symbol RPRX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags

FAQ

What is the current stock price of Royalty Pharma (RPRX)?

Royalty Pharma (RPRX) last closed at $68.45.

What is the market cap of Royalty Pharma (RPRX)?

The market cap of Royalty Pharma (RPRX) is approximately $39.3B.